NCT07444242 Accelerated Treatment of Depressive Patients With tDCS
| NCT ID | NCT07444242 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Regensburg |
| Condition | Major Depressive Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2026-04-01 |
| Primary Completion | 2027-11-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2026-04-01 with a primary completion date of 2027-11-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A randomized, controlled three-arm study is planned to investigate the effectiveness and feasibility of an accelerated home-based tDCS application (3 weeks of transcranial direct current stimulation at home, twice daily). A total of 30 patients with depression (10 per group), who are currently not taking and have no history of taking antidepressant medication, will be randomly assigned to either an active tDCS condition, a sham (placebo) tDCS condition, or a waitlist control group. The latter two groups will receive active tDCS treatment after completion of the control phase. This study represents a continuation of the pilot study GSUND DAHOAM (Ethics approval: 20-2091-101; Dragon et al., 2024).
Eligibility Criteria
Inclusion Criteria: * Sex: female, male, non-binary * Age: 18-70 years * Diagnosis of depression: no current or past psychiatric medication (current episode and history) * Provision of informed consent to participate * Sufficient proficiency in the German language Exclusion Criteria: * Presence of contraindications for tDCS (e.g., electrical implants or metallic objects in the body such as a cardiac pacemaker or insulin pump, dermatological conditions affecting the scalp) * Neurological disorders (e.g., cerebrovascular events, neurodegenerative diseases, epilepsy, brain malformations, or a history of severe head injury) * Participation in another clinical trial on depression within the 3 months prior to treatment initiation * Pregnancy or breastfeeding
Contact & Investigator
Berthold Langguth, Prof, PhD
PRINCIPAL INVESTIGATOR
University of Regensburg
Frequently Asked Questions
Who can join the NCT07444242 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Major Depressive Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07444242 currently recruiting?
Yes, NCT07444242 is actively recruiting participants. Contact the research team at stefan.schoisswohl@ukr.de for enrollment information.
Where is the NCT07444242 trial being conducted?
This trial is being conducted at Regensburg, Germany.
Who is sponsoring the NCT07444242 clinical trial?
NCT07444242 is sponsored by University of Regensburg. The principal investigator is Berthold Langguth, Prof, PhD at University of Regensburg. The trial plans to enroll 30 participants.